Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors

Journal of Medicinal Chemistry

Volumn 59, Issue 8, 2016, Pages 3886-3905

  Daydé Cazals, Bénédicte ^a   Fauvel, Bénédicte ^a   Singer, Mathilde ^a   Feneyrolles, Clémence ^a   Bestgen, Benoit ^a   Gassiot, Fanny ^a   Spenlinhauer, Aurélia ^a   Warnault, Pierre ^a   Van Hijfte, Nathalie ^a   Borjini, Nozha ^a   Chevé, Gwénaël ^a   Yasri, Abdelaziz ^a  

^a OriBase Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2 METHYL 5 [(1H PYRROLE 3 CARBONYL) AMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [(2 METHYL PYRIDINE 4 CARBONYL) AMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [(2 TRIFLUOROMETHYL PYRIDINE 4 CARBONYL) AMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [(5 METHYL PYRIDINE 3 CARBONYL) AMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [(5 TRIFLUOROMETHYL PYRIDINE 3 CARBONYL) AMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [3 (4 METHYL IMIDAZOL 1 YL) 5 TRIFLUOROMETHYL BENZOYLAMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [4 (2 METHYL THIAZOL 4 YL) BENZOYLAMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [4 (4 METHYL PIPERAZIN 1 YLMETHYL) BENZOYLAMINO] BENZOYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [2 METHYL 5 [4 (4 METHYL PIPERAZIN 1 YLMETHYL) BENZOYLAMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID; 5 [2 METHYL 5 [4 (4 METHYL PIPERAZIN 1 YLMETHYL) BENZOYLAMINO] BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYLAMIDE; 5 [5 [(1H INDOLE 5 CARBONYL) AMINO] 2 METHYL BENZYLAMINO] 1H PYRROLO[ 2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [5 [(BENZO[1,3]DIOXOLE 5 CARBONYL) AMINO] 2 METHYL BENZYLAMINO] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [5 [4 (3 DIMETHYLAMINO PYRROLIDIN 1 YLMETHYL) 3 TRIFLUOROMETHYL BENZOYLAMINO] 2 METHYL BENZOYLAMINO] 1H PYRROLO[2,3 B] PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 5 [5 [4 (3 DIMETHYLAMINO PYRROLIDIN 1 YLMETHYL) 3 TRIFLUOROMETHYL BENZOYLAMINO] 2 METHYL PHENOXYMETHYL] 1H PYRROLO[2,3 B]PYRIDINE 2 CARBOXYLIC ACID METHYL ESTER; 7 AZAINDOLE DERIVATIVE; AFATINIB; ANTINEOPLASTIC AGENT; BAFETINIB; DASATINIB; ERLOTINIB; IMATINIB; INDOLE DERIVATIVE; N [3 [(2 ACETYL 1H PYRROLO[2,3 B]PYRIDIN 5 YLAMINO) METHYL] 4 METHYL PHENYL] 4 (3 DIMETHYLAMINO PYRROLIDIN 1 YLMETHYL) 3 TRIFLUOROMETHYL BENZAMIDE; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PONATINIB; REGORAFENIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; 7-AZAINDOLE DIMER; PROTEIN KINASE INHIBITOR;

A549 CELL LINE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EC50; HEPG2 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IN VITRO STUDY; LEUKEMIA CELL; MAXIMUM PLASMA CONCENTRATION; MITSUNOBU REACTION; MOLECULAR DOCKING; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; STEREOSPECIFICITY; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BLOOD; CHEMISTRY; MALE; PATCH CLAMP TECHNIQUE; SYNTHESIS;

ANIMALS; CELL PROLIFERATION; DRUG DESIGN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; MALE; MICE; PATCH-CLAMP TECHNIQUES; PROTEIN KINASE INHIBITORS;

EID: 84968912266     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00087     Document Type: Article

References (23)

1. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting Cancer with Small Molecule Kinase Inhibitors Nat. Rev. Cancer 2009, 9 (1) 28-39 10.1038/nrc2559
2. Knapp, S.; Sundström, M. Recently Targeted Kinases and Their Inhibitors - the Path to Clinical Trials Curr. Opin. Pharmacol. 2014, 17, 58-63 10.1016/j.coph.2014.07.015
3. Gerlinger, M.; Rowan, A. J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; Begum, S.; McDonald, N. Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; Santos, C. R.; Nohadani, M.; Eklund, A. C.; Spencer-Dene, B.; Clark, G.; Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P. A.; Swanton, C. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing N. Engl. J. Med. 2012, 366 (10) 883-892 10.1056/NEJMoa1113205
4. Klein, C. A. Selection and Adaptation during Metastatic Cancer Progression Nature 2013, 501 (7467) 365-372 10.1038/nature12628
5. Gossage, L.; Eisen, T. Targeting Multiple Kinase Pathways: A Change in Paradigm Clin. Cancer Res. 2010, 16 (7) 1973-1978 10.1158/1078-0432.CCR-09-3182
6. Dar, A. C.; Das, T. K.; Shokat, K. M.; Cagan, R. L. Chemical Genetic Discovery of Targets and Anti-Targets for Cancer Polypharmacology Nature 2012, 486 (7401) 80-84 10.1038/nature11127
7. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the Cancer Kinome through Polypharmacology Nat. Rev. Cancer 2010, 10 (2) 130-137 10.1038/nrc2787
8. Chevé, G.; Bories, C.; Fauvel, B.; Picot, F.; Tible, A.; Daydé-Cazals, B.; Loget, O.; Yasri, A. De Novo Design, Synthesis and Pharmacological Evaluation of New Azaindole Derivatives as Dual Inhibitors of Abl and Src Kinases MedChemComm 2012, 3 (7) 788-800 10.1039/c2md20104f
9. Fauvel, B.; Coisy-Quivy, M.; Vivier, S.; Chevé, G.; Boriès, C.; Daydé-Cazals, B.; Feneyrolles, C.; Bestgen, B.; Delon, L.; Dufies, M.; Auberger, P.; Loget, O.; Yasri, A. Anti-Tumor Activity of Novel Compounds Targeting BCR-ABL, c-SRC and BCR-ABLT315I in Chronic Myelogenous Leukemia Am. J. Cancer Sci. 2013, 2 (1) 28-36
10. Getlik, M.; Grütter, C.; Simard, J. R.; Klüter, S.; Rabiller, M.; Rode, H. B.; Robubi, A.; Rauh, D. Hybrid Compound Design to Overcome the Gatekeeper T338M Mutation in cSrc J. Med. Chem. 2009, 52 (13) 3915-3926 10.1021/jm9002928
11. Seeliger, M. A.; Nagar, B.; Frank, F.; Cao, X.; Henderson, M. N.; Kuriyan, J. C-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty Structure 2007, 15 (3) 299-311 10.1016/j.str.2007.01.015
12. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571) Cancer Res. 2002, 62 (15) 4236-4243
13. Choi, H. G.; Ren, P.; Adrian, F.; Sun, F.; Lee, H. S.; Wang, X.; Ding, Q.; Zhang, G.; Xie, Y.; Zhang, J.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W.; Mestan, J.; Gray, N. S.; Sim, T. A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-Abl J. Med. Chem. 2010, 53 (15) 5439-5448 10.1021/jm901808w
14. Koroleva, E. V.; Kadutskii, A. P.; Farina, A. V.; Ignatovich, J. V.; Ermolinskaya, A. L.; Gusak, K. N.; Kalinichenko, E. N. A Practical Synthesis of 4-[(4-Methylpiperazin-1-Yl)methyl]benzoic Acid-the Key Precursor toward Imatinib Tetrahedron Lett. 2012, 53 (38) 5056-5058 10.1016/j.tetlet.2012.06.107
15. Chevé, G.; Daydé-Cazals, B.; Fauvel, B.; Boriès, C.; Yasri, A. New Azaindole Derivatives As Inhibitors of Protein Kinases. WO2014102378 A1, July 3, 2014.
16. Pessina, A.; Malerba, I.; Gribaldo, L. Hematotoxicity Testing by Cell Clonogenic Assay in Drug Development and Preclinical Trials Curr. Pharm. Des. 2005, 11 (8) 1055-1065 10.2174/1381612053381648
17. Hassan, S. B.; Haglund, C.; Aleskog, A.; Larsson, R.; Lindhagen, E. Primary Lymphocytes as Predictors for Species Differences in Cytotoxic Drug Sensitivity Toxicol. In Vitro 2007, 21 (6) 1174-1181 10.1016/j.tiv.2007.03.009
18. Schade, A. E.; Schieven, G. L.; Townsend, R.; Jankowska, A. M.; Susulic, V.; Zhang, R.; Szpurka, H.; Maciejewski, J. P. Dasatinib, a Small-Molecule Protein Tyrosine Kinase Inhibitor, Inhibits T-Cell Activation and Proliferation Blood 2007, 111 (3) 1366-1377 10.1182/blood-2007-04-084814
19. Lee, K. C.; Ouwehand, I.; Giannini, A. L.; Thomas, N. S.; Dibb, N. J.; Bijlmakers, M. J. Lck Is a Key Target of Imatinib and Dasatinib in T-Cell Activation Leukemia 2010, 24 (4) 896-900 10.1038/leu.2010.11
20. Trott, O.; Olson, A. J. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading J. Comput. Chem. 2010, 31 (2) 455-461 10.1002/jcc.21334
21. Goodsell, D. S.; Olson, A. J. Automated Docking of Substrates to Proteins by Simulated Annealing Proteins: Struct., Funct., Genet. 1990, 8 (3) 195-202 10.1002/prot.340080302
22. Wang, R.; Lai, L.; Wang, S. Further Development and Validation of Empirical Scoring Functions for Structure-Based Binding Affinity Prediction J. Comput.-Aided Mol. Des. 2002, 16 (1) 11-26 10.1023/A:1016357811882
23. The PyMol Molecular Graphics System, version 0.99rc6; Schrodinger, LLC: New York, 2015.